Related Studies of IMC-1 for Fibromyalgia
IMC-1 is a combination of anti-viral famciclovir and anti-inflammatory celecoxib. The basis of using the drug as treatment is its potential effectiveness in suppressing the herpes virus. Currently, the drug has already completed Phase 2 trials, a double-blinded and placebo-controlled study done by some experts in the medical field. In the study, 143 fibromyalgia participants were randomly given either IMC-1 or a placebo over a 16-week treatment period. Researchers observed and evaluated the participants during the 16 weeks. At the end of the study, participants who took IMC-1 showed less fibromyalgia pain and lower pain scores. This group also reported less fatigue. In general, participants tolerated the drug well.
This study showed a potential treatment option for pain and symptoms of fibromyalgia. It also suggests that suppressing dormant herpes virus can improve the chronic pain syndrome. This finding may lead to more clues to the root of fibromyalgia. IMC is now coordinating with FDA in order to comply with requirements needed for Phase 3 trial which is targeting to commence end 2017.